Funding for Innovative Clinical Trials for Frontotemporal Degeneration


Must be received by 5:00 pm ET on the deadline date.

Letter of Intent
November 9, 2018

Invited Full Proposal
February 15, 2019


Average Duration

1–3 years with potential for follow-on funding

Average Award

$500,000-$2,000,000. Leveraging other sources of funding is encouraged.


Funding is open to researchers and clinicians in the U.S. and worldwide working in:

  • Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
  • Biotechnology companies that demonstrate a clear need for non-profit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.


Association for Frontotemporal Degeneration

Launched in 2016, the Treat FTD Fund is a joint effort by the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) to support clinical development of novel or repurposed drugs for FTD disorders. Running clinical trials in FTD patients will enable investigators to identify optimal approaches to targeting this unique patient population. In addition, trials supported by the Treat FTD Fund will complement efforts such as the FTD Biomarkers Initiative and the Accelerating Drug Discovery for FTD program by employing emergent advances in biomarker development and preclinical research.

Funding Priorities

Patient Population: The targeted population should include both genetic and sporadic forms of any FTD disorder, including behavioral variant FTD, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, and FTD/ALS. A clear description of the rationale for the mechanism of action in the targeted population must be included in the application.

Therapeutic Focus: Roughly 70% of FTD disorders occur sporadically. As in Alzheimer's and other neurodegenerative diseases, a variety of mechanisms, like inflammation, proteostasis, or epigenetics, become dysfunctional with age and can contribute to disease pathogenesis. While gene therapy approaches for the genetic causes of FTD disorders are of interest, we encourage applications that target some of the underlying mechanisms that may contribute to the sporadic forms of the disease. This RFP is agnostic to target and open to symptomatic and disease-modifying approaches. Both novel and repurposed therapies are encouraged.

Behavioral and social interventions, as well as lifestyle modifications, will not be considered.

Clinical Design: The RFP will support clinical proof-of-concept and pilot proof-of-mechanism studies. Phase 0/1 studies in healthy volunteers assessing pharmacodynamic outcomes will also be accepted for review. Innovative clinical trial designs and exploratory endpoints are encouraged. Specifically, outcome measures that apply to heterogeneous FTD populations (e.g. markers of pathology due to various causes) should be included in the trial design. Multidomain biomarkers that define grouping should also be considered.


Leveraging of existing resources, clinical coordination centers/networks, and patient registries are highly encouraged.

Relevant resources include:


Applications should include:

  • Confirmation of drug supply
  • IRB-ready clinical trial protocol
  • Explicit plan for data sharing and/or making available the results publicly available

Applications will be confidentially reviewed by a Joint Steering Committee appointed by the ADDF and AFTD. Applications from biotechnology companies will also be reviewed by ADDF's external Business Advisory Board.


Review the Application Instructions for steps on applying.




For program-related inquiries, please contact:
Lauren Friedman, PhD, Director, Scientific Affairs

Nadine Tatton, PhD, Scientific Director, AFTD

For application submission inquiries, please contact:
Grants and Mission-Related Investments Team